SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 344 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.66 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,102,341 | +13.2% | 174,083 | +6.9% | 0.02% | +30.8% |
| Q2 2023 | $18,641,909 | -20.7% | 162,783 | -4.5% | 0.01% | -18.8% |
| Q1 2023 | $23,500,015 | -4.7% | 170,500 | -10.4% | 0.02% | -11.1% |
| Q4 2022 | $24,659,074 | +13.2% | 190,300 | -3.5% | 0.02% | +12.5% |
| Q3 2022 | $21,787,000 | +49.1% | 197,100 | +1.1% | 0.02% | +60.0% |
| Q2 2022 | $14,610,000 | -4.4% | 194,900 | -0.4% | 0.01% | +11.1% |
| Q1 2022 | $15,280,000 | +1.6% | 195,600 | +17.1% | 0.01% | 0.0% |
| Q4 2021 | $15,038,000 | -2.9% | 167,000 | -0.2% | 0.01% | -10.0% |
| Q3 2021 | $15,481,000 | +19.5% | 167,400 | +0.5% | 0.01% | +25.0% |
| Q2 2021 | $12,951,000 | -39.5% | 166,600 | -42.0% | 0.01% | -42.9% |
| Q1 2021 | $21,403,000 | -55.4% | 287,173 | +2.1% | 0.01% | -58.8% |
| Q4 2020 | $47,971,000 | +18.5% | 281,373 | -2.4% | 0.03% | +6.2% |
| Q3 2020 | $40,482,000 | -13.6% | 288,273 | -1.4% | 0.03% | -20.0% |
| Q2 2020 | $46,863,000 | +65.6% | 292,273 | +1.0% | 0.04% | +33.3% |
| Q1 2020 | $28,306,000 | -6.4% | 289,373 | +23.5% | 0.03% | -3.2% |
| Q4 2019 | $30,243,000 | +64.5% | 234,373 | -4.0% | 0.03% | +55.0% |
| Q3 2019 | $18,384,000 | -4.0% | 244,073 | +93.7% | 0.02% | -4.8% |
| Q2 2019 | $19,146,000 | +31.6% | 126,000 | +3.2% | 0.02% | +31.2% |
| Q1 2019 | $14,553,000 | +19.5% | 122,100 | +9.4% | 0.02% | 0.0% |
| Q4 2018 | $12,179,000 | -30.6% | 111,600 | +2.8% | 0.02% | -20.0% |
| Q3 2018 | $17,540,000 | +24.6% | 108,600 | +2.0% | 0.02% | +25.0% |
| Q2 2018 | $14,077,000 | +78.4% | 106,500 | 0.0% | 0.02% | +60.0% |
| Q1 2018 | $7,891,000 | +36.2% | 106,500 | +2.3% | 0.01% | +66.7% |
| Q4 2017 | $5,792,000 | +28.5% | 104,100 | +4.7% | 0.01% | +20.0% |
| Q3 2017 | $4,509,000 | +56.6% | 99,400 | +16.4% | 0.01% | +66.7% |
| Q2 2017 | $2,879,000 | +13.9% | 85,400 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $2,528,000 | +12.1% | 85,400 | +3.9% | 0.00% | -25.0% |
| Q4 2016 | $2,255,000 | -55.3% | 82,200 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $5,048,000 | +243.4% | 82,200 | +6.6% | 0.01% | +300.0% |
| Q2 2016 | $1,470,000 | +4.2% | 77,100 | +3.2% | 0.00% | -33.3% |
| Q1 2016 | $1,411,000 | -40.7% | 74,700 | +21.1% | 0.00% | -50.0% |
| Q4 2015 | $2,380,000 | +27.1% | 61,700 | +5.8% | 0.01% | +20.0% |
| Q3 2015 | $1,872,000 | +18.1% | 58,300 | +11.9% | 0.01% | +25.0% |
| Q2 2015 | $1,585,000 | +129.0% | 52,100 | 0.0% | 0.00% | +100.0% |
| Q1 2015 | $692,000 | -3.4% | 52,100 | +5.3% | 0.00% | -33.3% |
| Q4 2014 | $716,000 | -17.0% | 49,500 | +21.0% | 0.00% | 0.0% |
| Q3 2014 | $863,000 | -29.1% | 40,900 | 0.0% | 0.00% | -40.0% |
| Q2 2014 | $1,218,000 | +31.2% | 40,900 | +6.0% | 0.01% | +25.0% |
| Q1 2014 | $928,000 | +65.1% | 38,600 | +39.9% | 0.00% | +100.0% |
| Q4 2013 | $562,000 | -55.1% | 27,600 | +4.2% | 0.00% | -60.0% |
| Q3 2013 | $1,252,000 | +17.9% | 26,500 | -5.0% | 0.01% | 0.0% |
| Q2 2013 | $1,062,000 | – | 27,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |